PROSER2-AS1: A Potential Drug Target and Biomarker (G219731)

Target Name: PROSER2-AS1

NCBI ID: G219731

PROSER2-AS1

Other Name(s): PROSER2 antisense RNA 1

PROSER2-AS1: A Potential Drug Target and Biomarker

PROSER2-AS1, also known as PROSER2-AS1 RNA, is a non-coding RNA molecule that has been identified as an attractive drug target and biomarker for various diseases, including cancer. Its unique structure and functional characteristics make it an ideal candidate for further research in the field of nanotechnology, gene therapy, and regenerative medicine.

The PROSER2 gene is located on chromosome 6p11.2 and encodes a protein that is involved in various cellular processes, including cell adhesion, migration, and invasion. The AS1 gene, which is located on the same chromosome, encodes a non-coding RNA molecule that has been shown to play a role in regulating gene expression and cell survival.

When PROSER2-AS1 is expressed in cells, it interacts with the protein AS1 to form a complex that is involved in the regulation of cellular processes, including cell adhesion, migration, and invasion. This interaction between PROSER2-AS1 and AS1 has been shown to promote the growth and survival of cancer cells, making it a potential drug target.

One of the key advantages of PROSER2-AS1 as a drug target is its nanoscale properties. The AS1 protein is known to have a nanoscale interface, which allows for efficient delivery of small molecules and other therapeutic agents to the target cells. This interface also allows for the targeted delivery of nanoscale particles, such as nanoparticles, which can be used to deliver drugs directly to the target cells.

Another advantage of PROSER2-AS1 is its expression profile. The expression of PROSER2-AS1 has been shown to be highly dependent on the cell type and the presence of the AS1 protein. This allows for the targeted delivery of drugs to specific cell types, which can improve the effectiveness of the drug treatment.

In addition to its potential as a drug target, PROSER2-AS1 has also been shown to be a promising biomarker for various diseases, including cancer. The expression of PROSER2-AS1 has been shown to be elevated in various types of cancer, including breast, lung, and ovarian cancer. This suggests that PROSER2-AS1 may be a useful biomarker for the diagnosis and treatment of these diseases.

The ability of PROSER2-AS1 to interact with the AS1 protein also makes it a potential target for small molecules that can modulate the activity of the AS1 protein. This suggests that PROSER2-AS1 may be a useful target for the development of new therapeutic agents that can modulate the activity of AS1 protein and improve the effectiveness of drug treatment.

In conclusion, PROSER2-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases. Its unique nanoscale properties and expression profile make it an ideal candidate for further research in the field of nanotechnology, gene therapy, and regenerative medicine. Further studies are needed to determine the full potential of PROSER2-AS1 as a drug target and biomarker.

Protein Name: PROSER2 Antisense RNA 1

The "PROSER2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PROSER2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets